New Zealand markets close in 3 hours 43 minutes
  • NZX 50

    11,032.90
    -167.14 (-1.49%)
     
  • NZD/USD

    0.5733
    +0.0002 (+0.04%)
     
  • NZD/EUR

    0.5834
    +0.0002 (+0.03%)
     
  • ALL ORDS

    6,760.60
    +100.80 (+1.51%)
     
  • ASX 200

    6,555.00
    +93.00 (+1.44%)
     
  • OIL

    81.56
    +0.33 (+0.41%)
     
  • GOLD

    1,671.90
    +3.30 (+0.20%)
     
  • NASDAQ

    11,164.78
    -329.05 (-2.86%)
     
  • FTSE

    6,881.59
    -123.80 (-1.77%)
     
  • Dow Jones

    29,225.61
    -458.13 (-1.54%)
     
  • DAX

    11,975.55
    -207.73 (-1.71%)
     
  • Hang Seng

    17,165.87
    -85.01 (-0.49%)
     
  • NIKKEI 225

    26,422.05
    0.00 (0.00%)
     
  • NZD/JPY

    82.8010
    +0.0540 (+0.07%)
     

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

·1-min read
Quoin Pharmaceuticals, Inc.
Quoin Pharmaceuticals, Inc.

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live call can also be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call may be accessed on the Quoin Pharmaceuticals website under the Investors section:

https://investors.quoinpharma.com/news-and-events/events-and-presentations.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341